StephanieSmith-MarroneMD

PubMed

• 95 citations
  Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes
  Jarushka Naidoo, Maria Laureana Santos-Zabala, Tunc Iyriboz, Kaitlin M. Woo, Camelia S. Sima, John J. Fiore, Mark G. Kris, Gregory J. Riely, Piro Lito, Afsheen Iqbal, ...> ;Clinical Lung Cancer. 2016 Sep 1
• 17 citations
  Employment and return to work following chemoradiation in patient with HPV-related oropharyngeal cancer
  Shrujal S. Baxi, Talya Salz, Han Xiao, Coral L. Atoria, Alan L. Ho, Stephanie Smith-Marrone, Eric J. Sherman, Nancy Y. Lee, Elena B. Elkin, David G. Pfister> ;Cancers of the Head & Neck. 2016 Jun 3
• 4 citations
  Phase II Study of a Non-Platinum–Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas
  Maria Catherine Pietanza, Matthew D. Hellmann, John J. Fiore, Stephanie Smith-Marrone, Ethan Basch, Lawrence H. Schwartz, Michelle S. Ginsberg, Marwan Shouery, Samanth...> ;Journal of Thoracic Oncology. 2016 Jun 1
• 2 citations
  Revision of immunosuppression in a solid organ transplant recipient leads to complete remission of metastatic undifferentiated carcinoma.
  Abigail Waldman, AnnMarie Liapakis, William S. Asch, Stephanie Smith-Marrone, Oscar R. Colegio> ;JAAD Case Reports. 2015 Nov 1
• 28 citations
  Phase II trial of bevacizumab + cetuximab + cisplatin with concurrent intensity-modulated radiation therapy for patients with stage III/IVB head and neck squamous cell...
  Matthew G. Fury, Han Xiao, Eric J. Sherman, Shrujal S. Baxi, Stephanie Smith-Marrone, Karen D. Schupak, R.M. Gewanter, Daphna Y. Gelblum, Sofia Haque, Heiko Schöder, J...> ;Head & Neck. 2016 Apr 1
• 17 citations
  Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III–IVB head and neck squamous cell car...
  Matthew G. Fury, Eric J. Sherman, Shyam Rao, Suzanne L Wolden, Stephanie Smith-Marrone, Boris Mueller, Kenneth K.-S. Ng, P.R. Dutta, Daphna Y. Gelblum, J. L. Lee, Rong...> ;Annals of Oncology. 2014 Mar 1
• 28 citations
  A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m2 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
  Matthew G. Fury, Eric J. Sherman, Donna Lisa, Neeraj Agarwal, Kenneth M. Algazy, Bruce Brockstein, Corey J. Langer, Dean Lim, Ranee Mehra, Sandeep K. Rajan, Susan H. K...> ;Journal of the National Comprehensive Cancer Network. 2012 Nov 1
• A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m2 for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell...
  Fury MG, Sherman EJ, Lisa DM, Agarwal N, Algazy KM, Brockstein B, Langer CJ, Lim D, Mehra R, Rajan SK, Jafri N, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marron...> ;J. Clin. Oncol.. 2011-05-20
• Join now to see all